Heroin-assisted treatment (HAT) is an evidence-based treatment option for opioid use disorder (OUD), available in a limited number of countries. Norway implemented a 5-year HAT project in 2022, aiming to assess its effectiveness and its potential integration into the country’s OUD treatment system. This study describes and compares patients’ baseline characteristics from the Oslo and Bergen HAT clinics, providing a comprehensive picture of the unique population and the real-world application of HAT.
Methods:
This cross-sectional study examines the baseline characteristics of consenting HAT patients within the first 2 years of operation (n = 86). Self-reported questionnaires gathered sociodemographics, previous treatment experiences, self-reported crime, and substance use, as well as motivations and expectations for treatment. Comparisons between the clinics were carried out using t-tests, Mann–Whitney U tests, Chi-square, and Fisher’s exact test.
Results:
The majority of the patients were enrolled at the Oslo clinic (76%) and were male (80%). At admission, the average age was 45.9, with a significantly younger group in Bergen (42.5 vs 47.3, P < .05). While no patients reported being unhoused, 17% noted unstable housing within the preceding month. Unemployment was prevalent (91%) alongside previous treatment experiences (95%), with a median of 2 prior medication types. In the 3 months preceding HAT initiation, 78% of patients reported being victims of crime, and 44% committed at least one crime. Over their lifetime, 2 in 5 participants (41%) had experienced an unwanted overdose and 43% had shared syringes and equipment.
Conclusion:
This study reveals a cohort experiencing societal marginalization, including unstable housing, unsatisfactory prior OUD treatment, high-risk behaviors, and frequent interactions with criminal activities, predominantly as victims. While the Oslo and Bergen clinics serve a similar patient profile, notable differences emerged in the reasons for discontinuing past OUD treatment and crime-related factors.
BahjiAChengBGraySStuartH.Mortality among people with opioid use disorder: a systematic review and meta-analysis. J Addict Med. 2020;14(4):e118-e132. doi:10.1097/adm.0000000000000606
2.
DegenhardtLBucelloCMathersB, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32-51. doi:10.1111/j.1360-0443.2010.03140.x
3.
O’ConnorAMCousinsGDurandLBarryJBolandF. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020;15(5):e0232086. doi:10.1371/journal.pone.0232086
4.
SantoTJrClarkBHickmanM, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979-993. doi:10.1001/jamapsychiatry.2021.0976
5.
VolkowNDJonesEBEinsteinEBWargoEM.Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019;76(2):208-216. doi:10.1001/jamapsychiatry.2018.3126
6.
StrangJVolkowNDDegenhardtL, et al. Opioid use disorder. Nat Rev Dis Primers. 2020/01/09 2020;6(1):3. doi:10.1038/s41572-019-0137-5
7.
BellJStrangJ.Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82-88.
8.
SrivastavaAKahanMNaderM.Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?Can Fam Physician. 2017;63(3):200-205.
9.
MattickRPBreenCKimberJDavoliM.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Db Syst Rev. 2014;2014(2):CD002207.
10.
TimkoCSchultzNRCucciareMAVittorioLGarrison-DiehnC.Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22-35. doi:10.1080/10550887.2016.1100960
11.
SmartR.Evidence on the Effectiveness of Heroin-Assisted Treatment. RAND Corporation; 2018.
12.
StrangJGroshkovaTUchtenhagenA, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5-14. doi:10.1192/bjp.bp.114.149195
13.
SmartRReuterP.Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials. Addiction. 2022;117(3):518-531. doi:10.1111/add.15601
14.
BellJBelackovaVLintzerisN.Supervised injectable opioid treatment for the management of opioid dependence. Drugs. 2018;78(13):1339-1352. doi:10.1007/s40265-018-0962-y
15.
EllefsenRWüsthoffLECArnevikEA.Patients’ satisfaction with heroin-assisted treatment: a qualitative study. Harm Reduct J. 2023;20(1):73. doi:10.1186/s12954-023-00808-8
16.
McNairRMonaghanMMontgomeryP.Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: a context-focused systematic review. Drug Alcohol Depend. 2023/04/06/ 2023;247:109869. doi:10.1016/j.drugalcdep.2023.109869
17.
Oviedo-JoekesEMarchJCRomeroMPerea-MillaE. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev. 2010;29(1):75-80.
EllefsenR.Changing drug policy: the emergence of heroin clinics in Norway. Nord Stud Alcohol Drugs. 2023;41:14550725231207251. doi:10.1177/14550725231207251
24.
MyklebustLHEideDArnevikEA, et al. Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study. BMC Health Serv Res. 2024;24(1):398. doi:10.1186/s12913-024-10767-w
GedeonCSandellMBirkemoseI, et al. Standards for opioid use disorder care: An assessment of Nordic approaches. Nord Stud Alcohol Drugs. 2019;36(3):286-298. doi:10.1177/1455072518815322
BuktenASkurtveitSWaalHClausenT.Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. Addict Behav. Oct 2014;39(10):1504-1509. doi:10.1016/j.addbeh.2014.05.007
32.
BuktenAStavsethMRClasuenT.From restrictive to more liberal: variations in mortality among patients in opioid maintenance treatment over a 12-year period. BMC Health Serv Res. 2019;19(1):553. doi:10.1186/s12913-019-4382-9
33.
KlimasJHamiltonM-AGorfinkelLAdamACullenWWoodE.Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10(1):216. doi:10.1186/s13643-021-01764-9
34.
EdvardsenHMEClausenT.Opioid related deaths in Norway in 2000–2019. Drug Alcohol Depend. 2022;232:109281. doi:10.1016/j.drugalcdep.2022.109281
MilellaMSD’OttavioGDe PirroSBarraMCaprioliDBadianiA.Heroin and its metabolites: relevance to heroin use disorder. Transl Psychiatry. 2023;13(1):120. doi:10.1038/s41398-023-02406-5
Oslo University Hospital. Retningslinje. HABiO. Obligatorisk bruk av opioidscore før og etter inntak av diacetylmorfin (DAM) [Mandatory use of opioid score before and after intake of diacetylmorphine (DAM).]. 2024. Accessed February 15, 2024. https://ehandboken.ous-hf.no/document/143458
41.
Oviedo-JoekesENosykBBrissetteS, et al. The North American Opiate Medication Initiative (NAOMI): profile of participants in North America’s first trial of heroin-assisted treatment. J Urban Health. 2008;85(6):812-825. doi:10.1007/s11524-008-9312-9
42.
MelisFHesseMEideD, et al. Who receives heroin-assisted treatment? A comparison of patients receiving opioid maintenance treatment in Denmark. Drug Alcohol Depend. 2024;254:111051. doi:10.1016/j.drugalcdep.2023.111051
MullerAESkurtveitSClausenT.Many correlates of poor quality of life among substance users entering treatment are not addiction-specific. Health Qual Life Outcomes. 2016;14:39. doi:10.1186/s12955-016-0439-1
SælørKTKippenesMKlevanTAndvigE.A tale from the Glass Dome: a narrative analysis of social housing, living conditions and recovery. Nord Welf Res. 2021;6(1):44-55. doi:10.18261/issn.2464-4161-2021-01-05
HaasenCVertheinUEiroa-OrosaFJSchäferIReimerJ.Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results from a German randomised controlled trial. Eur Addict Res. 2010;16(3):124-130.
49.
SkjærvøIClausenTSkurtveitSAbelKFBuktenA.Similarities and differences in victimization risk factors for nonoffending and offending substance users. Vict Offenders. 2018;13(4):526-541.
50.
VertheinUBonorden-KleijKDegkwitzP, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction. 2008;103(6):960-966; discussion 967-968. doi:10.1111/j.1360-0443.2008.02185.x
51.
PoulterHLWalkerTAhmedD, et al. More than just ‘free heroin’: caring whilst navigating constraint in the delivery of diamorphine assisted treatment. Int J Drug Policy. 2023;116:104025. doi:10.1016/j.drugpo.2023.104025
BlankenPHendriksVMHuijsmanIAvan ReeJMvan den BrinkW.Efficacy of cocaine contingency management in heroin-assisted treatment: results of a randomized controlled trial. Drug Alcohol Depend. 2016;164:55-63. doi:https://doi.org/10.1016/j.drugalcdep.2016.04.018
55.
RileyFHarrisMPoulterHL, et al. ‘This is hardcore’: a qualitative study exploring service users’ experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England. Harm Reduct J. 2023;20(1):66. doi:10.1186/s12954-023-00785-y
56.
KarowAReimerJSchäferIKrauszMHaasenCVertheinU.Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend. 2010;112(3):209-215. doi:10.1016/j.drugalcdep.2010.06.009
57.
Oviedo-JoekesEGuhDBrissetteS, et al. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend. 2010;111(1):50-57. doi:10.1016/j.drugalcdep.2010.03.016
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
